Investigating treatments for retinopathy of prematurity using VEGF and calcitriol
Mechanism of intravitreal VEGF-A165a and topical calcitriol for the treatment of retinopathy of prematurity
This study is looking at how to better understand and treat retinopathy of prematurity (ROP) in premature babies by using special imaging techniques in mice to find safer ways to help their eyes grow healthy blood vessels.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10918271 on NIH RePORTER |
What this research studies
This research focuses on understanding and treating retinopathy of prematurity (ROP), a condition affecting premature infants that leads to abnormal retinal blood vessel growth. The principal investigator, Dr. Olachi Mezu-Ndubuisi, utilizes advanced imaging techniques to visualize retinal changes in a mouse model and aims to explore the regulation of vascular endothelial growth factor (VEGF) to develop safer therapies. By correlating structural and functional changes in the retina, the research seeks to identify effective treatment strategies that minimize adverse effects associated with current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are premature infants diagnosed with retinopathy of prematurity.
Not a fit: Patients who are not premature or do not have retinopathy of prematurity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for retinopathy of prematurity, potentially improving outcomes for affected infants.
How similar studies have performed: Previous research has shown promise in using VEGF modulation for treating similar conditions, indicating potential for success in this approach.
Where this research is happening
Rochester, United States
- University of Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Mezu-Ndubuisi, Olachi Joy — University of Rochester
- Study coordinator: Mezu-Ndubuisi, Olachi Joy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.